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ABSTRACT
Purpose: Flavopiridol, a small molecule pan-cyclin
inhibitor, has been shown to enhance the radiation response of
tumor cells both in vitro and in vivo. The clinical utility of
flavopiridol, however, is limited by toxicity, previously
attributed to pleiotropic inhibitory effects on several targets
affecting multiple signal transduction pathways. Here we
utilized zebrafish embryos to investigate radiosensitizing effects
of flavopiridol in normal tissues. Methods and Materials:
Zebrafish embryos at the 1-4 cell stage were treated with 500
nM flavopiridol or injected with 0.5 pmol antisense
hydroxylprolyl-phosphono nucleic acid oligomers to reduce
cyclin D1 expression, then subjected to ionizing radiation (IR)
or no radiation. Results: Flavopiridol-treated embryos
demonstrated a 2-fold increase in mortality following exposure
to 40 Gy by 96 hours post fertilization (hpf) and developed
distinct radiation-induced defects in midline development
(curly-up phenotype) at higher rates when compared to embryos
receiving IR only. Cyclin D1-deficient embryos had virtually
identical IR sensitivity profiles when compared to embryos
treated with flavopiridol. This was particularly evident for the
IR-induced curly-up phenotype, which was greatly exacerbated
by both flavopriridol and cyclin D1 downregulation.
Conclusions: Treatment of zebrafish embryos with flavopiridol
enhanced radiation sensitivity of zebrafish embryos to a degree
that was very similar to that associated with downregulation of
cyclin D1 expression. These results are consistent with the
hypothesis that inhibition of cyclin D1 is sufficient to account
for the radiosensitizing action of flavopiridol in the zebrafish
embryo vertebrate model.
Keywords: flavopiridol; cyclin D; hydroxyprolyl-phosphono
peptide nucleic acids; ionizing radiation; radiosensitizer
INTRODUCTION
Flavopiridol, a small molecule semi-synthetic
flavonoid inhibitor of cyclin dependent kinases 1, has been
shown to enhance the radiation response of tumor cells both in
vitro 2 and in vivo 3 model systems. However, the clinical utility
of this synthetic flavone as an anti-cancer therapeutic has been
disappointing, in part, due to dose-limiting toxicity. In addition
to the potent inhibition of cyclin-dependent kinases (CDKs), and
consequently cyclin function, numerous “off-target” activities
have been ascribed to the synthetic flavone, including inhibition
of numerous signal transduction cascades involving the EGFR,
PKA, PKC, HIF-1 and NF-B, to name but a few 4, 5. To
investigate the radiosensitizing effects of flavopiridol on normal
tissues, we examined the response of zebrafish embryos to
ionizing radiation (IR) with and without flavopiridol
pretreatment.
In order to elucidate whether the radiosensitizing action
of flavopiridol is due to inhibition of its primary pharmacologic
target, we compared flavopiridol effects on the radiation
response of zebrafish embryos to those associated with cyclin
D1 (ccnd1) downregulation achieved by antisense
hydroxylprolyl-phosphono peptide nucleic acid (HypNA-pPNA)
oligomers. Previously, we demonstrated the viability and
phenotypic characteristics of zebrafish embryos microinjected
with the antisense ccnd1 HypNA-pPNA 16-mer described
below 6.
Since cyclin D1 is involved in G1/S checkpoint
control, abrogation of its function by antisense downregulation
should block the progression of cells into S phase, a known
radioresistant part of the cell cycle 7. The cyclin D1-inhibited
cells should, therefore, be more sensitive to the effects of IR
than their uninhibited controls. Flavopiridol has previously been
shown to lower the level of cyclin D1 in human ovarian cancer
cells as one its pleiotropic mechanisms of radiosensitization 2.
In this work, we describe the effect of IR exposure on
ccnd1 knockdown embryos as compared to the radiation
response of wild-type embryos treated with flavopiridol prior to
IR exposure. Thus we hereby test the hypothesis that the
radiosensitization phenotype exhibited by flavopiridol is due to
its cyclin inhibitory effect.
MATERIALS AND METHODS
Embryo harvesting and maintenance
Zebrafish husbandry, embryo collection,
dechorionation, and embryo maintenance were performed
according to accepted standard operating procedures 8 and with
approval by the Institutional Animal Care and Use Committee at
Thomas Jefferson University. Zebrafish were maintained in the
Zebrafish Core Facility of the Kimmel Cancer Center at Thomas
Jefferson University at 28.5°C on a 14-h light/10-h dark cycle,
and embryos were staged as described 9.
Flavopiridol treatment
Groups of 15 newly fertilized zebrafish embryos were
treated with either 0 or 500 nM flavopiridol, generously
provided by Aventis (Bridgewater, NJ), in 10 mL of zebrafish
embryo medium (EM) 8 immediately after fertilization. Fresh
flavopiridol was added again every 24 h up to 120 h. Statistical
analysis was performed using a one-tailed student’s t-test.
Antisense HypNA-pPNA treatment
Antisense (N-GTGCTCCATATCTTCA-C) and single
mismatch (N-GTGCTCCAaATCTTCA-C) 16-mer HypNA-
pPNAs targeting the zebrafish ccnd1 mRNA initiation region
were obtained from Active Motif (Carlsbad, CA). Melting
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temperature (Tm) analysis revealed a 6°C lower Tm in the
single mismatch sequence relative to that for the targeted ccnd1
antisense sequence 6. For HypNA-pPNA microinjection into
zebrafish, a final concentration of 0.5 mM of each
oligonucleotide was prepared in 1:9 (v:v) phenol red dye and
phosphate-buffered saline, and ~1 nL injected into groups of 15
zebrafish embryos at the 1–4 cell stage using a nitrogen gas
pressure injector (Harvard Apparatus, Cambridge, MA).
Statistical analysis was performed using a one-tailed student’s t-
test.
Radiation exposure
All protocols using radiation were approved by the
Radiation Safety Committee of Thomas Jefferson University.
Embryos 24 hours postfertilization (hpf) were exposed to doses
varying from 0 to 40 Gy using a Gammacell 40 low-dose 137Cs
laboratory irradiator (AECL, Kanata, Canada) or 250 kVp X-ray
machine (PanTak, East Haven, CT). After irradiation, embryos
were incubated at 28.5°C for 24 h, dechorionated, and
maintained at 28.5°C for up to 144 h to evaluate morphology
and survival. Photomicrography of representative embryos was
performed using a Leica M2FLIII microscope (Leica, Wetzlar,
Germany) at 50× magnification.
RESULTS
Control and flavopiridol-treated zebrafish embryos
were exposed to IR at doses of 0, 10, 20, or 40 Gy at 24 h post-
fertilization (hpf). IR produced dose-dependent alterations of
normal embryo morphogenesis, as we reported previously 10,
with 100% of control embryos demonstrating a characteristic
aberrant dorsal tail curvature, designated “curly-up,” by 48 hpf
after treatment with 40 Gy (Fig. 1). In contrast, pretreatment
with 500 nM flavopiridol alone produced no gross
developmental defects in the embryos, but resulted in the curly-
up phenotype following exposure to a 50% lower dose of IR (20
Gy) than required to produce the same radiation-induced
teratogenic effects in corresponding control embryos (Fig. 1).
The survival of irradiated embryos pretreated with
flavopiridol was adversely affected to a greater extent than
embryos solely exposed to IR (Fig. 2). Specifically, exposure to
20 Gy IR produced 100% mortality by 144 hpf in the pretreated
embryos, whereas 97.0 ± 4.2% of similarly irradiated control
embryos remained viable (P=0.010). Following 40 Gy IR, none
of the flavopiridol treated embryos survived, while 55 ± 7.1% of
similarly irradiated control embryos were still alive at 120 hpf
(P=0.028).
The effect of ccnd1-specific HypNA-pPNA oligomer
antisense knockdown of ccnd1 transcripts on the radiation
response of zebrafish embryos was similarly examined.
Embryos were microinjected with phenol red, ccnd1 antisense
or single mismatch 16-mer HypNA-pPNAs by 1 hpf and then
exposed to IR at doses of 0, 10, 20, or 40 Gy at 24 hpf. A dose-
dependent alteration of normal embryo development was again
observed 24 hours following irradiation, with 100% of phenol
red-injected and mismatch-injected control embryos
demonstrating the curly-up phenotype at the highest dose of IR
tested (Fig. 3 and data not shown). Perturbation of normal
cyclin function with ccnd1 HypNA-pPNA produced multiple
morphologic abnormalities in the zebrafish embryos at baseline,
including microcephaly, microophthalmia, micrognathia, and
pericardial edema, in agreement with our previous observations
6
. These phenotypic alterations were exacerbated by radiation
treatment. Of note, cyclin D1 reduction by ccnd1 HypNA-pPNA
oligomers resulted in the curly-up phenotype 24 h following
irradiation with only 20 Gy (Fig. 3), as was seen following
flavopiridol pretreatment (Fig. 1).
The enhanced radiosensitivity of zebrafish embryos
with deficient cyclin D1 expression also translated into reduced
survival following IR exposure, as was observed in the
flavopiridol-treated fish. Control phenol red and single
mismatch microinjected embryos were resistant to 20 Gy IR
exposure, with 100% survival at 144 hpf, whereas only 24 ±
5.7% of the embryos with reduced cyclin D1 activity remained
viable at 144 hpf (p=0.017) (Fig. 4 and data not shown). This is
comparable to the effect on survival observed following
irradiation of embryos pretreated with flavopiridol (Fig. 2). As
was also observed in the flavopiridol treated embryos, none of
the embryos with antisense-reduced cyclin D1 were alive
following 40 Gy IR exposure by 120 hpf, while 43.5 ± 5.0% of
similarly irradiated control embryos remained viable (p=0.026)
(Fig. 4).
48hpf Untreated 500nMFlavopiridol
0Gy
10Gy
20Gy
40Gy
Figure 1: Flavopiridol-mediated radiosensitization of zebrafish
embryos. Embryos were treated with 0 (untreated) or 500 nM
flavopiridol. Embryos were then exposed to 0-40 Gy -radiation
at 24 hpf. Morphology at 48 hpf of representative embryos from
replicate experiments is shown at 50× magnification. Note the
aberrant dorsal tail curvature (“curly-up” phenotype), as well as
reduced head and eye size in irradiated control embryos
receiving a dose of 40 Gy, and in treated embryos receiving
doses of 20 and 40 Gy.
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Figure 2: Effect of flavopiridol treatment on zebrafish viability
following ionizing radiation exposure. Embryos were either
treated daily with 500 nM flavopiridol or left untreated, exposed
to various doses of IR, and monitored for survival up to 144 hpf.
Data points show the mean and standard deviation of replicate
experiments using 15 embryos per group. Survival of embryos
following exposure to 40 Gy IR was significantly better in the
untreated controls than in the flavopiridol pre-treated embryos at
120 hpf (p=0.029).
Figure 3: ccnd1 antisense-mediated radiosensitization of
zebrafish embryos. Embryos were injected with either vehicle
(phenol red) or ccnd1 antisense HypNA-pPNA and exposed to
0-40 Gy -radiation at 24 hpf. Morphology at 48 hpf of
representative embryos from replicate experiments is shown at
50× magnification. Note the aberrant dorsal tail curvature
(“curly-up” phenotype), as well as reduced head and eye size in
irradiated control embryos receiving a dose of 40 Gy, and in
treated embryos receiving doses of 20 and 40 Gy.
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PNA- 40 GyFigure 4: Effect of ccnd1 antisense HypNA-pPNA treatment on
zebrafish viability following ionizing radiation exposure.
Embryos were injected with either vehicle (phenol red) or
ccnd1-targeted HypNA-pPNA and monitored for survival up to
144 hpf. Data points show the mean and standard deviation of
replicate experiments using 15 embryos in each group. Survival
of embryos following exposure to 40 Gy IR was significantly
better in the controls than in the ccnd1-downregulated embryos
at 120 hpf (p=0.026).
DISCUSSION
Flavopiridol, a semi-synthetic pan-cyclin inhibitor 1,
has been reported to sensitize a variety of human cancer types,
including esophageal 11, prostate 12, ovarian 2, colon and gastric
13 carcinomas as well as leukemia cells 14, to ionizing radiation.
The radiosensitizing effect of the flavonoid has also been
demonstrated in vivo using a murine model system with
xenografted human tumors 15 and syngeneic mouse tumors 2, 3.
While flavopiridol was the first cyclin-dependent kinase
inhibitor tested in clinical trials 16, the results of these trials have
been discouraging due to the unexpected, significant toxicity of
the agent, both when given as monotherapy 17 and when co-
administered with various chemotherapeutic drugs 18, 19. The
sole trial examining the combination of flavopiridol with
radiation therapy for unresectable pancreatic cancer has only
recently been approved for patient accrual (ClinicalTrials.gov),
and thus the toxicity of this combined modality approach in
humans is still to be determined. Furthermore, because
flavopiridol, in addition to being a very potent pan-cyclin
inhibitor, has been shown to interfere with numerous other
cellular processes involving diverse signal transduction
pathways 4, 5, the exact mechanism of flavopiridol’s normal
tissue toxicity is not easily determined.
To begin to address this issue of normal tissue toxicity
with flavopiridol, particularly in relation to IR exposure, we
employed zebrafish embryos as a living, dynamic vertebrate
model. Previously, we demonstrated the utility of this model
system to characterize the radiation response and its modulation
by different chemical agents 10. In the present work, we
investigated the effect of treating the embryos with 500 nM
flavopiridol, determined to be the biologically active
concentration 16, alone and in conjunction with IR exposure. At
baseline, flavopiridol had no gross effect on normal embryonic
morphology and survival, but when administered before IR, the
embryos demonstrated dorsal tail curvature (“curly-up”
phenotype) and significantly reduced viability compared with
similarly irradiated control embryos.
To determine if the flavopiridol effect was due, in part,
to cyclin inhibition, we transiently down-regulated the
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expression of cyclin D1 using specific HypNA-pPNA antisense
oligonucleotides. The previously reported6 morphologic
perturbations of normal embryonic development, identified as
microophthalmia, microcephaly and dorsal tail curvature, with
the affected sites corresponding to areas of high cyclin D1
expression in the developing embryos 6, 20. were observed in the
cyclin D1-reduced embryos, even without radiation treatment.
The antisense ccnd1 HypNA-pPNA 16-mer lowered
the Western blot level of cyclin D1 in treated embryos
dramatically, compared to vehicle-injected controls6. Similarly,
intratumoral injection of human peptide-CCND1 PNA-peptide
lowered the Western blot level of cyclin D1 in human breast
cancer xenografts in immunocompromised mice by about half
21
.
Peptide nucleic acid derivatives, like morpholino
phosphorodiamidates, do not activate RNase H, and as a result
do not lower the levels of their target mRNAs, but inhibit
mRNA translation solely by hybridization arrest 22. When we
directly tested that point by incubating human MCF7 breast
cancer cells in the presence of an antisense MYC PNA-peptide
for 24 hr, no reduction in the level of MYC mRNA in the
extracted RNA was observed by QRT-PCR 23.
Given the similarities between the phenotype of cyclin
inhibition and radiation exposure alone, effectively interpreting
and quantifying the additional effects of radiation is clearly
recognized as a difficult task. This problem, however, was
expected, particularly in light of modulating the expression of
genes involved in homeostatic functions during development,
and is not dissimilar to difficulties routinely encountered using
knockout mouse technology.
Because cyclin D1 facilitates the G1/S transition in the
cell cycle, ccnd1 inhibition should theoretically block the cells
at this checkpoint, known to be an exquisitely radiosensitive
part of the cell cycle 7. Following exposure to IR, the “curly-
up” phenotype is more apparent in the antisense injected
embryos than in the corresponding irradiated controls. Further,
the survival curves for the ccnd1-inhibited zebrafish showed
significantly increased sensitivity to IR. This finding is
essentially indistinguishable from that observed in irradiated
embryos pretreated with flavopiridol.
Collectively, these results support the hypothesis that
the inhibition of cyclin D1 is sufficient to account for the
radiosensitizing effects of flavopiridol in zebrafish embryos.
This work additionally confirms the utility of zebrafish as a
model system for studying the pharmacogenetics of radiation
effects in vertebrates. Our results confirm and extend our
previous observations that zebrafish embryos provide a
powerful in vivo model to identify and characterize additional
novel targets, namely those involved in the cell cycle and DNA
damage response, for pharmacological modulation of radiation
resistance in patients exposed to radiation. These results also
suggest the feasibility of zebrafish embryos for high-throughput
screening of radiosensitizers, given the readily scoreable
phenotype following radiation exposure.
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